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Abstract
I In nt tr ro od du uc ct ti io on n: : The short-term effects of multifactorial intervention for cardio-
vascular disease (CVD) prevention on renal function and serum uric acid (SUA)
levels in patients with stage 3 chronic kidney disease (CKD) and multiple CVD
risk factors are unclear. The aim of the study was to prospectively assess these
effects.
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   This post hoc analysis of 5 "best practice" studies
involved patients with multiple CVD risk factors. Estimated glomerular filtration
rate (eGFR) was assessed using the Modification of Diet in Renal Disease (MDRD)
formula. Among the 4,153 patients, 1,235 (29.7%) had stage 3 CKD (eGFR between
30 and 59 ml/min/1.73 m2). A baseline visit was followed by a concerted effort
from previously trained physicians to improve adherence to lifestyle advice and
optimize drug treatment, including a statin, for all vascular risk factors. After 
6 months eGFR and SUA levels were re-evaluated. 
R Re es su ul lt ts s: :   The intervention improved compliance to lifestyle measures and
increased the use of evidence-based medication, including a statin. There was
also a 5.6% increase in eGFR (p < 0.001) in patients with stage 3 CKD and a 6.1%
reduction in SUA levels (p < 0.001). Among patients with stage 3 CKD, 127 (10.3%)
improved to stage 2 CKD and 9 (0.7%) advanced to stage 4 CKD by the end of
the 6-month study period. There were no major side-effects.
C Co on nc cl lu us si io on ns s: :   Multitargeted intervention, including a statin, may improve renal
function and reduce SUA levels within 6 months, thus offsetting 2 potential CVD
risk factors in high-risk patients. 
K Ke ey y   w wo or rd ds s: :   renal function, uric acid, dyslipidaemia, diabetes mellitus, hypertension,
metabolic syndrome, multifactorial intervention, statin.
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Introduction
The world-wide prevalence of chronic kidney dis-
ease (CKD) is high and is increasing rapidly [1]. In
2010, 26 million American adults had CKD and mil-
lions of others are at increased risk. According to
the National Kidney Foundation classification [1-5],
more than 8 million had stage 3 CKD and 0.5% had
stage 4 or 5 CKD [1-5].
Total mortality, cardiovascular disease (CVD)
events and hospitalizations markedly increase as
renal function declines [6-8]. Even moderately
decreased estimated glomerular filtration rate
(eGFR) and low levels of albuminuria predict CVD
and all-cause mortality in the general population
[9]. This has led to the suggestion to incorporate
kidney function in the Framingham equation to
improve CVD risk stratification [10].
There are considerable gaps in our knowledge on
how to manage patients with CKD [11]. We showed
that statins improve renal function [12] and reduce
serum uric acid (SUA) levels [13] in patients with CVD
[12] and in those with CVD and metabolic syndrome
(MetS) or diabetes mellitus (DM) [14-16]. In the pri-
mary prevention setting, we recently reported that
long-term (42 months) multifactorial intervention,
including atorvastatin, improves renal function and
reduces CVD events in patients with MetS but with-
out CVD or DM [17]. The other relevant studies in
this field are considered in the discussion section. 
Dyslipidaemia may accelerate the decline of renal
function, and the coexistence of MetS, DM, or
hypertension is also associated with a faster rate
of decline, rendering early and effective interven-
tions of utmost importance [18]. This was also sug-
gested by the findings of the Study of Heart and
Renal Protection (SHARP), where pre-dialysis renal
function could not be improved by lipid-lowering
therapy [19].
The present analysis of 5 previous "best prac-
tice" studies was undertaken to investigate the ear-
ly (6-month) effects of multifactorial treatment on
renal function and SUA levels in high-risk patients
with multiple CVD risk factors.
Material and methods
The present study is a post hoc analysis of
changes in renal function in 5 independent studies
carried out from 2005 to 2010 [17, 20-23]. One study
[17] was performed by the Hellenic Atherosclerosis
Society and the other 4 studies were performed [20-
23] under the auspices of the Northern Greece
Bureau (Authority) of the Ministry of Health, the
Hellenic Atherosclerosis Society and the Greek Soci-
ety of General Practitioners. All studies received eth-
ical approval and informed consent was obtained
from all subjects before enrolment. The studies
incorporated in the present analysis are: 
1) Assessing The Treatment Effect in Metabolic syn-
drome without Perceptible diabeTes (ATTEMPT)
study, which included patients with MetS but
no DM or CVD [17];
2) implementation of strategy for the management
of overt dyslipidemia (IMPROVE-dyslipidemia)
study, which included patients with dyslipidaemia
with or without DM, with or without CVD [20];
3) standardized arrangement for a guideline-driven
treatment of the metabolic syndrome (SAGE-
METS) study, which included patients with MetS
but no CVD [21];
4) implementation of guidelines for the manage-
ment of arterial hypertension (IMPULSION) study,
which included patients with hypertension with
or without DM but no CVD [22];
5) initiative for a new diabetes therapeutic approach
in a Mediterranean country (INDEED) study,
which included patients with diabetes but no
CVD [23]. 
E En nd dp po oi in nt ts s
The primary endpoint of the studies was the
effect of multiple interventions on estimated CVD
risk. The primary endpoint of this post hoc joint
analysis was to investigate the early effect of mul-
tifactorial  treatment  on  renal  function  (eGFR) 
6 months after intervention initiation. The second-
ary endpoint was the effect of this treatment on
SUA levels.
D De ef fi in ni it ti io on n   o of f   M Me et tS S
This was according to the American Heart Asso-
ciation/National Heart, Lung, and Blood Institute
criteria [24].
S St tu ud dy y   d de es si ig gn n   – –   s st tu ud dy y   c co oh ho or rt t
All 5 studies had a similar protocol. They were
designed as “best practice” prospective studies.
Physicians from teaching hospitals (secondary care)
or health centres (primary care) recruited consecu-
tive consenting patients with DM, MetS, hyperten-
sion or dyslipidaemia who attended their outpatient
clinics. A total of 4,153 patients were included in the
present intention-to-treat analysis. The 1,123 patients
who were included in the ATTEMPT study [17] were
followed up for 3,5 years, whereas the patients in
the other 4 studies were followed up for 6 months.
However, in this post-hoc IMPERATIVE analysis,
ATTEMPT  patients  were  evaluated  for  the  first 
6 months, similarly to those of the other studies. In
all studies all patients were followed monthly by their
physicians for at least 6 months. Among the entire
analysis population (n = 4,153) 1,235 (29.7%) had
stage 3 CKD according to the National Kidney Foun-
dation definition [2], i.e. eGFR between 30 and 
59 ml/min/1.73 m2. The eGFR was calculated with
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the Modification of Diet in Renal Disease (MDRD)
formula [25]. No patient had stage 4 (15-29 ml/min/
1.73 m2) or 5 (< 15 ml/min/1.73 m2), according to the 
protocol of the original studies, while 1,424 patients
(34%) had stage 2 (60-89 ml/min/1.73 m2), 912 (22%)
stage 1 (> 90 ml/min/1.73 m2 + evidence of kidney
damage) CKD [2], and 582 (14%) had normal renal
function without any evidence of kidney damage. 
At the first visit, the personal and family med-
ical history and the drug treatment were recorded
on a specifically designed 1-page form. A physical
examination was also carried out. Subjects were
then invited to undergo laboratory tests at the hos-
pital after a 12 h fast, at which time a second phys-
ical examination was performed.
I In nt te er rv ve en nt ti io on n
Before the study initiation and during the study,
physicians attended a total of 7 educational meet-
ings. In 4 meetings, current guidelines for the man-
agement of hypertension, dyslipidaemia, MetS, DM
and obesity were presented, specific diets based
on the Greek variation of the Mediterranean diet
were shown and up-to-date treatment protocols
were discussed. The other 3 meetings were for the
solving of technical problems during the study. 
During the 6-month follow-up, an intensification
of treatment in terms of lifestyle advice, adminis-
tration of new drugs or titration of already pre-
scribed drugs was implemented, aiming to reach
multiple treatment targets. The physician advised
each patient to follow a healthier lifestyle and to
adhere to drug treatment. Patients were encour-
aged to follow a modified Mediterranean diet as
described in a brochure. Adherence to this diet was
assessed using a 10-unit scale. The study protocol
advised the use of orlistat in obese patients (body
mass index (BMI) > 30 kg/m2) and in overweight
patients who did not lose at least 4 kg during the
first 3 months. Apart from the brochure including
advice on how to achieve these goals, patients also
received education from dieticians (mainly in hos-
pitals) or from physicians (mainly in health centres)
who were also educated in providing nutritional
advice. Furthermore, special attention was drawn
to quitting smoking using certain appropriate meth-
ods (i.e. counselling, psychological support and nico-
tine replacement treatments).
F Fo ol ll lo ow w- -u up p
In Greece, prescriptions have to be “refilled”
monthly, and most of the drugs used have 90%
reimbursement. Consequently, patients had to visit
their physician every month. During these 6 visits
(after the start of the study), the physician tried to
improve the control of CVD risk factors (e.g. by
lifestyle advice, administration of new drugs, dose
titration or change of prescribed drugs). There was
a lifestyle evaluation and dose titration visit at the
6th treatment week and patients were then fol-
lowed at monthly intervals. At the 6th treatment
month (the final visit), the physician completed 
a 1-page form for each patient that included 2 ques-
tions. Does the patient still have CVD risk factors?
And if yes, what did the physician do about it? The
physician was aware of this question from visit 1
and we believe that this was a motivating factor. 
There  was  no  “control”  group  because  all
patients were at high CVD risk. It was therefore
deemed unethical to deprive them of appropriate
treatment. We used as control values those at base-
line before the implementation of the multifactor-
ial intervention.
L La ab bo or ra at to or ry y- -b ba as se ed d   a as ss se es ss sm me en nt t
Blood samples were collected from an antecu-
bital vein between 8 and 10 am, in a sitting posi-
tion, after a 12 h fast. Serum levels of total choles-
terol, high density lipoprotein cholesterol (HDL-C)
and triglycerides (TGs) were measured. Serum low
density lipoprotein cholesterol (LDL-C) levels were
calculated with the Friedewald formula (LDL-C
[mg/dl] = TC [mg/dl] – (TG [mg/dl]/5 + HDL-C
[mg/dl])). The non-HDL-C value was obtained by
subtracting the HDL-C value from that of total cho-
lesterol. Serum creatinine (SCr) was measured using
the Jaffe method. The same method was used in
all patients, and there were no changes in method-
ology during any of the interventional periods.
Serum alanine aminotransferase (ALT), aspartate
aminotransferase (AST), ʳ-glutamyl transpeptidase
(ʳ-GT), alkaline phosphatase (AP), creatine phos-
phokinase (CPK) levels and SUA levels were also
assessed. eGFR (ml/min/1.73 m2) was measured
using the Modification of Diet in Renal Disease
equation: eGFR = 175 × (SCr [mg/dl])–1.154 × (age
[years])–0.203 × (0.742 if female) [http://www.nkdep.
nih.gov/professionals/gfr_calculators/idms_con.
htm] [25]. All laboratories that performed these
tests followed the criteria of the World Health
Organization Lipid Reference Laboratories and ful-
filled internal and external validity control criteria.
All measurements in the same centre were per-
formed with the same methods in the same labo-
ratory, so that results would be comparable.
S St ta at ti is st ti ic ca al l   a an na al ly ys si is s
The analysis was carried out with the SPSS 19.00
software package (SPSS Inc., Chicago, IL). Variables
both at baseline and 6 months later were normal-
ly distributed, as evaluated with the Kolmogorov-
Smirnov test, so the results are presented as mean
± SD. The paired Student t-test and the ˇ2 test were
used to compare continuous and categorical vari-
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ables, respectively. A two-tailed p < 0.05 was con-
sidered significant.
Results
Among the 4,153 patients, 1,524 had CVD or DM
or both (secondary prevention or equivalent) and
2,629 were free of both CVD and DM (primary pre-
vention). Among the 4,153 patients, 29.7% (n = 1,235)
had stage 3 CKD. Among those, 23.1% (n = 285)
had DM and 15.3% (n = 189) had overt CVD. Among
stage 3 CKD patients, the following drugs were
used: all patients (n = 1,235) were on statins. Hyper-
tension was primarily managed with angiotensin-
converting enzyme inhibitors (ACE-I) or angiotensin
receptor blockers (ARBs; 45% and 31%, respective-
ly), and if needed with calcium channel blockers
(CCB, 30%) or low-dose hydrochlorothiazide (12.5
mg/day, 25%). If hypertension was not controlled,
selective ʲ-blockers (28%), centrally acting (14%) or
any other antihypertensives (9%) were used. Orli-
stat was used in 512 patients with a BMI > 30
kg/m2. Metformin, sulfonylureas and insulin were
used in patients with impaired fasting glucose
or DM. Metformin was also used in obese patients
(n = 452) with an eGFR > 45 ml/min/1.73 m2. The
drug treatment results refer to the 6th week (titra-
tion visit) to the 6th month period (end of study). 
At  the  6th treatment  month,  there  was  an
improvement (compared with baseline) in all CKD
and CVD risk factors in stage 3 CKD patients, (body
weight, fasting plasma glucose (FPG), systolic and
diastolic blood pressure, and lipid values; Table I). 
Those with stage 1 and 2 CKD had lower SUA lev-
els, lower BMI, and a lower incidence of MetS, com-
pared with stage 3 CKD patients. However, there
were no differences in smoking status, gender, drug
categories used, or in adherence to lifestyle advice.
The dropout rate was similar at all stages of CKD
and there were no clinical events in patients at any
stage of CKD during the study. 
In stage 3 CKD patients, multifactorial treatment
resulted in a 5.6% increase in eGFR (from 50 ±6 to
53 ±5 ml/min/1.73 m2; p < 0.001) and in a 6.1%
reduction in SUA levels (from 7.1 ±2.3 to 6.7 ±2.1
mg/dl; p < 0.001) (Table I and Figure 1). Among the
stage 3 CKD patients, 127 (10%) improved to stage
2 CKD and 9 (0.7%) advanced to stage 4 CKD by the
end of the 6-month study period. There were no
major side-effects of drug treatment.
Discussion
The IMPERATIVE analysis included both primary
and secondary prevention patients with hyperten-
sion, dyslipidaemia, MetS and DM, alone or (mainly)
in combination, and showed that a multifactorial
approach improves the use of evidence-based treat-
ment. In the overall population (n = 4,153), multi-
factorial treatment was not related to a significant
change in renal function. However, in patients 
(n = 1,235) with stage 3 CKD a significant 5.6% 
(p < 0.001) increase in eGFR and a 6.1% reduction
(p < 0.001) in SUA levels were recorded, thus off-
setting 2 predictors of CVD within 6 months.
Glomerular filtration rate is expected to decrease
with time [26] and this process is influenced by 
P Pa ar ra am me et te er r B Ba as se el li in ne e 6 6   m mo on nt th hs s V Va al lu ue e   o of f   p p   
Age [years] 57 ±6 ––
Male gender [%] 47 ––
Family history of CVD [%] 26 ––
Smoking [%] 29 23 < 0.001
Body mass index [kg/m2] 30 ±5 27 ±4 < 0.001
Body weight [kg] 81 ±7 76 ±5 < 0.001
Waist circumference [cm] 99 ±7 95 ±6 < 0.001
Systolic blood pressure  145 ±11 132 ±9 < 0.001
[mmHg]
Diastolic blood pressure  91 ±10 82 ±6 < 0.001
[mmHg]
Blood glucose [mg/dl] 110 ±16 97 ±12 < 0.001
Total cholesterol [mg/dl] 232 ±36 175 ±21 < 0.001
Triglycerides [mg/dl] 186 ±37 124 ±29 < 0.001
HDL-C [mg/dl] 45 ±14 48 ±7 < 0.001
LDL-C [mg/dl] 150 ±28 103 ±19 < 0.001
Estimated glomerular  50 ±6 53 ±5 < 0.001
filtration rate 
[ml/min/1.73 m2]
Serum uric acid [mg/dl] 7.1 ±2.3 6.7 ±2.1 < 0.001
T Ta ab bl le e   I I. . Change in measured parameters in patients
(n = 1,235) with stage 3 chronic kidney disease (CKD,
estimated glomerular filtration rate 30-59 ml/min/
1.73 m2) among the 4,153 patients included in the 
5 stu  dies
CVD – cardiovascular disease, HDL-C – high density lipoprotein cho-
lesterol, LDL-C – low density lipoprotein cholesterol
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several factors (e.g. DM, dyslipidaemia, hyperten-
sion, MetS and obesity) [26, 27]. Although CKD can
progress to end-stage renal disease (ESRD), patients
with stage 3 CKD are more likely to die of CVD
before they reach ESRD, since CKD is per se a potent
risk factor for CVD [28]. 
Meta-analyses have shown that statins slow the
rate of eGFR decline in patients with CKD [28, 29].
The Heart Protection Study [30] and a pooled analy-
sis of several pravastatin trials [31] showed that
simvastatin and pravastatin reduce the rate of kid-
ney function decline in patients with or at risk for
CVD. In the Greek Atorvastatin and Coronary-heart-
disease Evaluation (GREACE) study, we showed for
the first time that atorvastatin treatment signifi-
cantly increases eGFR whereas renal function dete-
riorated in untreated patients with coronary heart
disease (CHD) with or without MetS and with or
without DM [12, 14, 15]. This improvement in renal
function  was  independently  associated  with
a reduction in CVD events [12]. This benefit of ator-
vastatin treatment was confirmed in the Treating
to New Targets (TNT) trial in 10,001 patients with
stable CHD [32, 33]. In stage 3 CKD patients in TNT,
the increase in eGFR was significantly greater with
atorvastatin 80 mg/d than with 10 mg/day (9.9 vs.
6.6%, respectively; p < 0.005), suggesting that this
benefit is dose-related [32]. Moreover, the 3,107
patients who had CKD at baseline demonstrated
greater CVD comorbidity than those with normal
eGFR (n = 6,549) [33]. Compared with atorvastatin
10 mg/day, atorvastatin 80 mg/day reduced the rel-
ative risk of major CVD events significantly more in
those with CKD (by 32% vs. 15% in those with nor-
mal renal function) [33]. The Collaborative Atorvas-
tatin Diabetes Study (CARDS) [34] was a random-
ized placebo-controlled trial that included 2,838
pa  tients with type 2 DM and no prior CVD. At base-
line,  34%  of  patients  had  an  eGFR  of  30-59
ml/min/1.73 m2, and in those patients atorvastatin
10 mg/d was associated with a modest improve-
ment in the annual change in eGFR (p = 0.01), and
with substantial (42%) reduction in major CVD
events [34]. 
Studies with other hypolipidaemic drugs did not
show any improvement in renal function. The
SHARP trial included mostly patients with pre-dial-
ysis renal function (only 36% of patients had stage
3 CKD, while the rest had stage 4 or 5 (mean eGFR
26.6 ml/min/1.73 m2) [19]). These patients seem to
have crossed the point of no return [8, 10, 16] in
terms of kidney function, while LDL-C reduction was
modest (33 mg/dl). Nevertheless, in SHARP there
was a significant reduction in clinical events [19]. In
the Cholesterol and Recurrent Events (CARE) Trial
[35], among all CHD dyslipidaemic individuals with
an eGFR < 60 ml/min/1.73 m2), the eGFR decline in
the pravastatin group was not significantly differ-
ent from that in the placebo group. Moreover, in the
Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT) [36] in hyper-
tensive patients with moderate dyslipidaemia and
decreased eGFR, pravastatin was not superior to
usual care in preventing renal outcomes. This was
consistent across the strata of baseline eGFR. How-
ever, benefit from statin therapy may depend on
the  degree  of  the  cholesterol  level  decrease
achieved [36], and pravastatin (40 mg/day over 
4.8 years) only produced a < 10% fall in total cho-
lesterol. The Veterans' Affairs High-Density Lipopro-
tein Intervention Trial (VA-HIT) study [37] was a ran-
domized trial of gemfibrozil vs. placebo in 2531 men
with established CAD; 1046 men had CKD (most
had stage 2 and a few stage 3 CKD). The risk of sus-
tained increases in serum creatinine was increased
in gemfibrozil recipients compared with placebo 
(5.9% vs. 2.8%, p = 0.02) [37]. Fenofibrate caused an
acute, sustained plasma creatinine increase in the
Fenofibrate Intervention and Event Lowering in Dia-
betes (FIELD) and Action to Control Cardiovascular
Risk in Diabetes (ACCORD) studies [38]. However,
fenofibrate reduced albuminuria and slowed esti-
mated eGFR loss over 5 years, despite initially and
reversibly increasing plasma creatinine [38]. It
should be kept in mind that fibrates are meta  -
bolised in the kidney and stage 3 CKD or greater
might cause toxic accumulation of fibrates or their
metabolites in the blood [38]. The Assessment of
Lescol in Renal Transplantation (ALERT) trial inves-
tigated the effect of fluvastatin treatment on renal
function in renal transplant recipients [39]. Fluvas-
tatin had no detrimental effect on renal function,
or the risk of renal AEs, in renal transplant recipi-
ents with or without diabetes enrolled in ALERT.
However, these findings could not be generalized
because they were found in a special population.
Based on all the above, it seems that the effect of
a hypolipidaemic drug on renal function depends
on baseline renal function, LDL-C reduction, the
drug category (statin or fibrate), the specific drug,
and the dose used [16]. 
In the present study we recorded an increase in
eGFR and a reduction in SUA levels by the 6th treat-
ment week (titration visit; Figure 1). This early ben-
efit, which may be attributed to the pleiotropic
effects of statins, was also apparent in the GREACE
study [12, 14, 15]. Our findings in the present analy-
sis confirm this benefit in a variety of high-risk
patients. 
A meta-analysis showed that intentional mod-
est weight loss may reduce proteinuria and blood
pressure but does not affect the eGFR [40]. How-
ever, this could be viewed as a beneficial effect
because a decline in eGFR occurred in the control
groups of the included studies, while the eGFR did
not change during a mean follow-up of 7.4 months
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in patients who lost weight. Thus, weight loss
might reduce the risk for both CVD and CKD [41].
In addition, in patients with CKD, weight loss
reduced  proteinuria  and  blood  pressure  and
appeared to prevent further decline in renal func-
tion [40, 41]. Therefore, the 6% weight loss that we
observed in the present analysis because of lifestyle
advice and the use of orlistat in some patients 
(n = 512) might have contributed to renoprotection.
There is accumulating evidence that dysgly-
caemia without DM is also associated with renal
injury [42-44]. Furthermore, the prevalence of CKD
rises gradually as fasting glucose levels increase,
even well below the currently accepted threshold
of 126 mg/dl for diagnosing DM [44]. This correla-
tion remained significant after adjustment for age,
gender, ethnic group and the presence of hyper-
tension [44]. Thus, the reduction in fasting glucose
levels in our patients because of lifestyle advice and
treatment  with  metformin  in  some  patients 
(n = 452) might have played a role in the improve-
ment in renal function.
The  effective  management  of  hypertension
might also have contributed to renoprotection in
our analysis [45]. The increased activity of the renin-
angiotensin-aldosterone system (RAAS) is a key fac-
tor in the progression of CKD [46]. Angiotensin II
mediates systemic haemodynamic changes [47]
and plays an important role in promoting protein-
uria and progressive eGFR decline [47]. Therefore,
lowering blood pressure with drugs that block the
RAAS is useful in the management of patients with
CKD [47]. Thus, the use of RAAS blocking agents in
78% of our patients might have contributed to the
increase in eGFR.
Elevated SUA levels were related to increased
CVD risk in patients with MetS [48], non-alcoholic
fatty liver disease [49], CKD [50], CVD [51] and in
the general population [52]. A study with 14,262 per-
son-years in patients with or without CVD (43% and
57%, respectively) showed that for each 1 mg/dl
increase in SUA levels there was a 26% increase
(adjusted for multiple CVD risk factors) in the risk
of death [53]. Atorvastatin lowers SUA levels and
we have reported a 29% increase in CVD events for
every 1 mg/dl increase in SUA levels and a 24%
reduction in CVD events for every 1 mg/dl atorvas-
tatin-induced decrease in SUA levels [13]. In the
Losartan Intervention for Endpoint reduction in
hypertension (LIFE) study that compared losartan
with atenolol [54, 55], a 29% reduction in CVD
events was attributed to losartan-induced reduc-
tion in SUA levels [53, 54]. In the present analysis,
13% of patients were on losartan.
The present analysis has limitations. One is that
this is a post hoc analysis of the effects of multi-
factorial treatment on renal function and SUA lev-
els. Moreover, proteinuria and albuminuria, 2 param-
eters that may significantly influence CVD as well
as CKD risk, were not quantitatively assessed. The
short duration of the study is not a limitation
because we aimed to assess how soon these effects
become apparent. Changes in eGFR may be due to
functional or structural changes. In the long term,
the structural changes are the important ones. We
have shown in the past that this multifactorial ther-
apeutic approach, including a statin, results in an
increase of eGFR and in a reduction in SUA levels
[12, 17]. What was not known was the short-term
(6 month) effect, which might mainly derive from
functional changes. There was no control group
because all patients were at high CVD risk and we
considered that it was unethical to deprive them of
appropriate treatment. Data at the 6th month were
compared with those of baseline. Another option
was to use a control group on "usual care" and
compare the 6th month analysis results with the
"structured care" group. In this context, it is rele-
vant that all patients were on "usual care" prior to
recruitment to the 5 studies. Besides, the last trials
for multiple risk factor intervention using "usual
care" were performed during the 1970s [Multiple
risk factor intervention trial (MRFIT) [56] and the
Hypertension Detection and Follow-up Program
(HDFP) [57]], when both the exact impact of each
CVD risk factor and the benefit from reversing it
were not entirely clear. Data from the post hoc
analysis of the data from the Justification for the
Use of Statins in Prevention (JUPITER) trial (it includ-
ed 17,802 healthy men and women) were used to
predict  statin  treatment  effect  for  individual
patients based on existing risk level [58]. The accu-
racy of the prediction suggests that our conclusions
on "best practice" benefit may be generalised. 
In conclusion, this post hoc joint analysis of 
5 prospective “best practice studies” showed that
multifactorial intervention in patients with multiple
CVD risk factors and stage 3 CKD improves renal
function and lowers SUA levels early after treat-
ment initiation (within 6 months), thus offsetting
2 potential CVD risk factors. According to the
National Kidney Foundation, individuals with MetS,
DM, hypertension, dyslipidaemia and the elderly
are at high risk for CKD [1, 4]. Therefore, these
patients should be managed aggressively and the
present findings suggest that multifactorial inter-
vention is beneficial in this regard.
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